You are here: Industry Insights > CAR-T

News List

Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah fiercepharma
December 05, 2018
Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick.
Sartorius and Immunochina Partner to Advance Immunotherapy Development pharmafocusasia
December 04, 2018
Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals....
CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma worldpharmanews
December 04, 2018
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lym
First children set to receive Novartis’ Kymriah pharmatimes
November 28, 2018
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Novartis focusing on cutting CAR-T costs ahead of EU launches pharmaphorum
November 26, 2018
Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies that could potentially be cheaper to produce.
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy pharmafile
November 20, 2018
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that were being manufactured into a CAR-T cell therapy, according to researchers at the University of Pennsylvania.
F1 Oncology Expands Operations contractpharma
November 18, 2018
Shanghai EXUMA will develop these clinical programs into multicenter trials under a centralized regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC)
F1 Oncology Expands Operations contractpharma
November 18, 2018
Shanghai EXUMA will develop these clinical programs into multicenter trials under a centralized regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC)
Calithera compound empowers immuno-oncology therapies by targeting metabolic signals fiercebiotech
November 02, 2018
Can targeting one metabolic signaling pathway have completely opposite effects on different subsets of T cells? In the case of glutamine metabolism, the answer seems to be ...
England's cost watchdogs nix Novartis' Kymriah for adults fiercepharma
September 30, 2018
Cost watchdogs in England turned away Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page